Brief: OSE Immunotherapeutics Announces Positive Analysis Of First Data Of CoVepiT

Ose Immunotherapeutics SA

30/11/2021 06:35

Nov 30 (Reuters) - OSE IMMUNOTHERAPEUTICS SA  OSE.PA :
    * OSE IMMUNOTHERAPEUTICS PROVIDES AN UPDATE ON THE FIRST
POSITIVE
RESULTS AND CLINICAL DEVELOPMENT OF COVEPIT, ITS MULTI-TARGET
T-CELL ANTI-COVID VACCINE
    * NEW CLINICAL DATA CONFIRM GOOD TOLERANCE OF COVEPIT AND A
VERY
GOOD LEVEL OF T CELL RESPONSE IN HEALTHY VOLUNTEERS VACCINATED
    * PROMISING PRECLINICAL EFFICACY SIGNALS GUIDE DEVELOPMENT
IN
IMMUNOCOMPROMISED PATIENTS WITH POOR ANTIBODY RESPONSE TO
PRESENT REGISTERED ANTI-COVID VACCINES
    * RESULTS ON 6-MONTH LONG-TERM MEMORY T RESPONSE, EXPECTED
IN Q1
OF 2022, WILL BE A KEY ELEMENT IN FURTHER CLINICAL DEVELOPMENT
    * COVEPIT EPITOPES* REMAIN INDEPENDENT OF MUTATIONS
IDENTIFIED IN
CURRENT AND EMERGING VARIANTS

Source text for Eikon:  ID:nBw5xY7lxa 
Further company coverage:  OSE.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))